Live feed08:45:00·1681dPRReleasevia QuantisnowKala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface DiseasesByQuantisnow·Wall Street's wire, on your screen.KALA· KALA BIO Inc.Health Care
